ModifiedHealth NetPolicy CP PHAR.417

Clinical Policy: Brexanolone (Zulresso)

Policy governing medical necessity and prior authorization criteria for brexanolone (Zulresso) for treatment of postpartum depression in eligible members across Commercial, HIM and Medicaid lines of business.

Policy Summary

PayerHealth Net

PolicyClinical Policy: Brexanolone (Zulresso)

Policy CodePolicy CP PHAR.417

Change TypeMaterial revisions to dosing, prescriber scope, age, and prior trial duration

Effective DateJun 1, 2019

Next Review Date

Key ActionObtain prior authorization with documentation showing diagnosis timing, age ≥15, severity assessment, prescriber specialty, and a failed 4-week antidepressant trial when applicable.

SourceLink

POLICY UPDATE CHANGES

Updated dosing regimens in Appendix B and removed commercially unavailable branded therapeutic alternatives.

Added obstetrician-gynecologist as an additional prescriber specialty and clinician able to confirm severe depression; added BDI and EPDS as additional depression scales.

Per updated prescribing information, indication and age requirements updated from adults 18 years to 15 years and older.

Shortened trial duration of antidepressant agents from 8 weeks to 4 weeks in 2Q 2023 review.

60 hoursstandard infusion duration

90 mcg/kg/hrmaximum infusion rate

≥15minimum FDA-approved patient age

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Brexanolone (Zulresso)

inv-01: Initial Approval Criteria for Zulresso

Covered when ALL of the following are met:

Initial approval

Severity criteria: Meet ONE of the following severity thresholds: HAMD >=24; PHQ-9 >=20; MADRS >=35; EPDS >=20; BDI >=29; OR documentation of severe depression from psychiatrist or obstetrician-gynecologist clinical interview.
Severity cutoffs per Appendix D; MADRS corrected to >=35 as noted in revisions.

Continued therapy monitoring: Adherence to prescribed 60-hour infusion regimen with documented tolerance to escalating infusion rates (30 -> 60 -> 90 mcg/kg/hr) and monitoring for adverse events; adjustments permitted for intolerance (e.g., maintain 60 mcg/kg/hr instead of 90 mcg/kg/hr).Maximum 90 mcg/kg/hr

Monitoring per REMS requirements and Appendix C boxed warning; continuous oximetry required.

inv-02: Coverage criteria for brexanolone infusion

Policy contains criteria related to diagnosis timing, severity, prior treatment trials, and prescriber qualifications.

Core coverage conditions: Member has a diagnosis of major depressive episode with onset no later than 4 weeks following delivery (per revised ACOG-aligned guidance); documentation of severe depression demonstrated by at least one accepted depression scale (e.g., MADRS >=35, PHQ-9, BDI, EPDS) or a clinical interview performed by a psychiatrist or obstetrician-gynecologist; prior treatment history consistent with a 4-week trial failure of one oral antidepressant at adequate dose unless contraindicated; prescriber is an authorized specialty (includes psychiatrist and OB-GYN per 2024 update); member meets age requirement (>=15 years).

Nested requirements include timing of onset, severity documentation, prescriber specialty, and shortened antidepressant trial duration (4 weeks).

Non‑FDA approved indications for brexanolone (Zulresso) are not authorized under this clinical policy unless the provider supplies sufficient documentation of efficacy and safety in accordance with the Plan's referenced off‑label use policies (CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid) or other applicable evidence‑of‑coverage documents.

When state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Providers should consult the applicable state Medicaid manual for specific coverage rules that supersede this policy.

Requests for re‑authorization or continued therapy with brexanolone are not permitted. Members must meet the initial approval criteria for any new request; continuation beyond the single authorized course will be denied.

The HCPCS codes listed in this policy are provided for informational purposes only and do not guarantee coverage. Inclusion or omission of codes does not determine payment — providers must submit claims using current coding guidance and include required clinical documentation to support coverage determinations.

Coding and Assessment Thresholds

HCPCS Codes referencedHCPCS

J1632

Injection, brexanolone, 1 mg

HAM-D (HAMD) severe threshold

Source contextSeverity cutoffs referenced in Appendix D (HAM-D scale definitions).

MADRS severe depression threshold corrected note

Corrected MADRS noteMADRS severe depression threshold corrected to >= 35 in the 2Q 2024/2025 policy updates; use MADRS >=35 when documenting severe depression.

Documentation alternativeIf no accepted scale meets severe cutoff, documentation of severe depression by psychiatrist or OB-GYN clinical interview is acceptable.

ReferenceCorrection and addition of clinical interview pathway noted in policy revision history.

Provider Requirements, Prior Authorization and Documentation

Prior Authorization

Prior Authorization Required with Clinical Criteria

Prior authorization is required for brexanolone (Zulresso) and requests must meet all initial approval criteria listed in the policy. Providers must obtain prior authorization before administration.

HCPCS: J1632 (Injection, brexanolone, 1 mg) — inclusion of a code does not guarantee coverage; verify current coding guidance

Documentation Required

Documentation and Indication Compliance

Provider must submit supporting documentation with the prior authorization request. Requests that lack required documentation or that are for non‑FDA indications without appropriate off‑label justification will be denied per applicable off‑label policies.

Acceptable documentation: office/clinic notes, hospital records, laboratory results, consultation notes, and other relevant clinical information
Off‑label coverage requires documentation of evidence per CPCPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid)

Definitions and Key Terms

Brexanolone (Zulresso) — drug definition and mechanism

Drug definitionBrexanolone (Zulresso) is a neuroactive steroid and a gamma-aminobutyric acid (GABAA) receptor positive modulator.

Therapeutic useApproved for treatment of postpartum depression (PPD).

Regulatory/administration noteAvailable only under controlled administration with monitoring due to risk of excessive sedation and loss of consciousness (REMS).

Postpartum depression (PPD) indication — FDA-approved indication and minimum age

FDA-approved indicationTreatment of postpartum depression (PPD).

Timing requirementDiagnosis must begin no earlier than third trimester and no later than 4 weeks postpartum for policy-covered use.

Infusion and Procedural Level-of-Care Requirements

inv-29: Infusion/Procedural behavioral health service

Admission for brexanolone infusion: Patient diagnosed with postpartum major depressive episode with onset within 4 weeks of delivery; severe depression confirmed by accepted instrument (e.g., MADRS >=35, PHQ-9, BDI, EPDS) or clinical interview by psychiatrist/OB-GYN; appropriate prescriber and documentation for outpatient-to-infusion site or inpatient administration; facility and staff capable of continuous oximetry monitoring and managing REMS requirements.

Level-of-care considerations include capacity for monitoring given boxed warning for excessive sedation and sudden loss of consciousness.

Continued stay criteria: Adherence to the 60-hour continuous infusion protocol with documented tolerance to dose escalations and ongoing monitoring for adverse events; allow dose adjustment for intolerance (e.g., remain at 60 mcg/kg/hr rather than escalate to 90 mcg/kg/hr).Maximum 90 mcg/kg/hr

See Appendix C for boxed warning; continuous oximetry required under REMS.

Available Treatment Modalities and Infusion Details

inv-30: Brexanolone (IV infusion) — modality criteria node

Administration and monitoring: Administer as a continuous IV infusion over 60 hours per specified titration schedule: 0–4 h 30 mcg/kg/hr; 4–24 h 60 mcg/kg/hr; 24–52 h 90 mcg/kg/hr (or 60 mcg/kg/hr if 90 not tolerated); 52–56 h 60 mcg/kg/hr; 56–60 h 30 mcg/kg/hr. Continuous oximetry monitoring is required due to risk of excessive sedation and sudden loss of consciousness; drug is available only through a REMS program.Maximum 90 mcg/kg/hr

Dose adjustments permitted for intolerance; see Appendix C boxed warning.

inv-31: Brexanolone infusion (Zulresso) — modality criteria node

Brexanolone infusion dosing: Administer as a continuous intravenous infusion over 60 hours with weight-based escalation: 0–4 h: 30 mcg/kg/hr; 4–24 h: 60 mcg/kg/hr; 24–52 h: 90 mcg/kg/hr (or 60 mcg/kg/hr if 90 not tolerated); 52–56 h: 60 mcg/kg/hr; 56–60 h: 30 mcg/kg/hr. Maximum dose 90 mcg/kg/hr. Associated HCPCS code J1632 is informational; prior authorization and clinical documentation required for coverage.

Background

Brexanolone (Zulresso) is a neuroactive steroid and GABAA receptor positive modulator approved for treatment of postpartum depression (PPD) in patients aged 15 years and older. It is administered as a weight‑based continuous intravenous infusion over a 60‑hour regimen with staged rate escalation and a maximum infusion rate of 90 mcg/kg/hr. Due to risks of excessive sedation and sudden loss of consciousness, administration requires continuous monitoring and is available through a REMS program.